NDAORALFOR SUSPENSION
Approved
Sep 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLAPEN-W (cyclacillin) is an oral penicillin-type antibiotic available as a suspension for oral administration. It was approved in 1979 and is used to treat bacterial infections susceptible to cyclacillin. The drug represents a legacy oral antibiotic in a crowded, mature market.
LOE Approaching
This legacy antibiotic faces LOE with moderate competitive pressure (30), suggesting a small, defensive brand team focused on market maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and LOE approaching, this product offers limited career advancement and stability risk. Roles available are primarily defensive: managing price, formulary access, and generic competition in a declining market. Most career-building opportunities would focus on cost management and transition planning rather than product growth.
Brand Manager
Worked on CYCLAPEN-W at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.